Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $232

Benzinga Newsdesk www.benzinga.com Positive 61.5%

Neg 0% Neu 0% Pos 61.5%

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $219 to $232.